Thu.Feb 08, 2024

article thumbnail

PBMs take bulk of blame as senators question BMS, J&J and Merck CEOs on high drug prices in US

Fierce Pharma

Thursday, when senators questioned three Big Pharma CEOs about the high price of drugs in the U.S., Health, Education, Labor and Pensions (HELP) committee chairman Bernie Sanders, I-Vermont, put th | CEOs from Bristol Myers Squibb, Johnson & Johnson and Merck faced tough questions from senators on why prices for drugs in the U.S. exceed those in other countries.

Education 292
article thumbnail

Five Ways AI Will Impact Clinical Trials This Year

MedCity News

The integration of AI technologies holds promise for enhancing outreach efforts, streamlining recruitment processes, and addressing long-standing barriers and biases that hinder diversity and inclusion in clinical trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AstraZeneca hit CEO Pascal Soriot's $45B revenue goal after all. But is Enhertu approaching a plateau?

Fierce Pharma

With $45.8 billion in 2023 revenues, AstraZeneca has met the $45 billion-by-2023 goal CEO Pascal Soriot established in 2014 when he was fending off a takeover bid from Pfizer. | AstraZeneca has met the $45 billion-by-2023 revenue goal that CEO Pascal Soriot established in 2014. But questions have emerged for one of the company's key growth drivers.

273
273
article thumbnail

BioNTech Pact and Stock Sale Infuse Autolus With $600M for Its Cell Therapies

MedCity News

Autolus will apply the capital to its CAR T-cell therapy currently under FDA review in cancer and in early clinical development in lupus. Meanwhile, BioNTech will gain access to Autolus’s cell therapy manufacturing assets as well as technologies that could support the R&D of in vivo therapies and antibody drug conjugates.

Sales 120
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Eli Lilly agrees to provide free and lower-priced insulin in Minnesota to resolve 2018 lawsuit

Fierce Pharma

After reaching a settlement with Minnesota’s attorney general, Eli Lilly can close the book on a yearslong lawsuit in the state. | The company will provide its insulin products at $35 per month and donate free insulin at 15 clinics over the next five years. Meanwhile, Minnesota's claims against Novo Nordisk and Sanofi remain ongoing.

235
235
article thumbnail

Why Experts Saw Cano Health’s Bankruptcy Coming From A Mile Away

MedCity News

Cano Health filed for bankruptcy this week — about three years after going public $4.4 billion SPAC merger. The industry reacted without surprise, with experts calling the bankruptcy a direct result of mismanagement, a quixotic growth strategy and poor market selection.

Marketing 119

More Trending

article thumbnail

Upsized Kyverna IPO Gets $319M to Bring CAR T-Therapy to Autoimmune Diseases

MedCity News

Cell therapies were first validated in cancer, but Kyverna Therapeutics aims to show they’re safe enough for autoimmune diseases. The biotech plans to deploy its IPO cash across clinical trials in lupus nephritis, multiple sclerosis, systemic sclerosis, and myasthenia gravis.

Biopharma 117
article thumbnail

‘The Top Line’: The most anticipated drug launches of 2024

Fierce Pharma

This week on “The Top Line,” we explore the most anticipated drug launches of 2024. | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028.

Sales 180
article thumbnail

Gilead drops CD47 drug magrolimab for blood cancers

pharmaphorum

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die than those in control groups.

Patients 112
article thumbnail

Roche's subcutaneous answer to AstraZeneca PNH drugs wins world-first approval in China

Fierce Pharma

China has become the first country to sign off on Roche’s paroxysmal nocturnal hemo | China has become the first country to sign off on Roche’s paroxysmal nocturnal hemoglobinuria (PNH) drug crovalimab, a subcutaneous answer to AstraZeneca’s infused treatments Soliris and Ultomiris. Roche’s subsidiary Chugai Pharmaceutical, which developed crovalimab and owns its rights in Japan and Taiwan, announced the approval of the humanized complement inhibitor C5 monoclonal antibody.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

RegenxBio advances two candidates to make waves in the CNS space

Pharmaceutical Technology

AFFINITY data has spurred RegenxBio towards a pivotal study for DMD while pivotal CAMPSIITE data has the company moving towards an FDA BLA.

FDA 111
article thumbnail

Fierce Pharma Asia—Leqembi’s slow uptake; Takeda’s pipeline culls; Roche’s world-first nod

Fierce Pharma

Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out. | Eisai said uptake of its Biogen-partnered Alzheimer's drug, Leqembi, will likely miss an early launch target. Takeda cut several cancer candidates in its latest pipeline clear-out.

Pharma 130
article thumbnail

Could the next Alzheimer’s drug discovery be… Viagra?

pharmaphorum

Epidemiological studies can often throw out intriguing and sometimes erroneous correlations between a variable and a disease, but UK scientists say a finding that Alzheimer’s disease seems to be less common in Viagra users warrants further investigation.

22
article thumbnail

Papa Launches Programs To Address Health-Related Social Needs, Improve Star Ratings

MedCity News

Companion care company Papa has created two programs for health plans: one that addresses social drivers of health and one that aims to improve health plans’ star ratings.

107
107
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

JCVI announces advice for 2024 spring COVID-19 vaccine programme

PharmaTimes

The committee has advised that the vaccine should be given to those at the highest risk

105
105
article thumbnail

MedCity News Launches Debunked, A Show Where We Slaughter Myths, Bad Practices and Sacred Cows in Healthcare

MedCity News

MedCity News is launching a new ongoing show called Debunked: Slaughtering Myths, Bad Practices and Sacred Cows in Healthcare. In this show, co-hosts Arundhati Parmar and Samir Batra will discuss healthcare news and call out things that seem utterly insane to us. The goal is to inspire change in the healthcare industry.

article thumbnail

Kyverna prices its IPO, seeking $319m for its cell therapies

pharmaphorum

Autoimmune disease CAR-T therapy specialist Kyverna has upsized its IPO to $319m in another sign of an improving #biotech financing environment

100
100
article thumbnail

Next-in-class combination treatment shows potential in cystic fibrosis

European Pharmaceutical Review

Vertex Pharmaceuticals’ once-daily small molecule vanzacaftor/tezacaftor/deutivacaftor (vanza triple) for cystic fibrosis (CF) has gleaned positive results in Phase III trials. The Phase III trials The clinical programme for the once daily vanza triple was comprised of two Phase III trials: SKYLINE 102 and SKYLINE 103, evaluating the efficacy of vanzacaftor (20 mg)/tezacaftor (100 mg)/deutivacaftor (250 mg) in cystic fibrosis patients 12 years and older with at least one F508del mutation or a m

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Roche gets first world okay for PNH drug crovalimab

pharmaphorum

China has become the first country in the world to approve Roche’s anti-complement C5 antibody crovalimab, the only treatment for the rare disorder paroxysmal nocturnal haemoglobinuria (PNH) that can be given by subcutaneous injection.

100
100
article thumbnail

Medicines access: Unlocking the immense potential in cell and gene therapy  

Pharmaceutical Technology

Despite several ground-breaking developments, pharmaceutical and biotech companies are often reluctant to invest in cell and gene therapy.

article thumbnail

Rapid microbiology testing market to value nearly $13bn by 2034

European Pharmaceutical Review

A report from Prophecy Market Insights on rapid microbiology testing has predicted that the market is anticipated to surpass $12.7 billion by 2034. Growth drivers of the global rapid microbiology testing market A rise in infectious diseases worldwide has increased demand for rapid and precise diagnostics. This has in turn accelerated growth of this market, the report stated.

article thumbnail

Researchers discover new type of memory B cell that remembers allergies

PharmaTimes

The cell could be a target for new immunotherapies for the chronic disease

97
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

BioNTech adds CAR-T manufacturing with $250m Autolus deal

pharmaphorum

BioNTech has taken a $200 million stake in Autolus in a private placement that will allow it to tap into the UK company’s manufacturing capacity for CAR-T therapies

article thumbnail

Anvatabart opadotin by Ambrx Biopharma for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Pharmaceutical Technology

Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

article thumbnail

Astellas adds digital to its top management team

pharmaphorum

Astellas appoints Nick Eshkenazi as chief digital and transformation officer (CTDO), the first time the pharma has included a digital role in its top management team

article thumbnail

Anvatabart opadotin by Ambrx Biopharma for Gastric Cancer: Likelihood of Approval

Pharmaceutical Technology

Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Gastric Cancer.

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Early Phase Trial Shows Promise of Amgen’s MariTide in Producing More Durable Weight Loss Results

Pharmaceutical Commerce

Data suggest that dosing of MariTide may be effectively tapered down and the drug may be taken less frequently over time compared with GLP-1 agonists such as Wegovy and Zepbound.

72
article thumbnail

FDA and EMA team up to expedite complex generic drug development

Pharmaceutical Technology

This initiative builds on the original parallel scientific advice programme launched by the FDA and EMA in 2021.

FDA 59
article thumbnail

Combination Therapy Reduces Blood Pressure for Those Taking Ibrutinib

Pharmacy Times

Ibrutinib and other Bruton tyrosine kinase inhibitors can cause the development of or worsen pre-existing hypertension.

58
article thumbnail

How payers and providers can leverage data analytics to provide better care for aging populations

Clarify Health

It is no exaggeration that the American healthcare industry faces a looming crisis: an increasing number of older adults with complex healthcare needs. Today, the 65-and-older population in the U.S. is just 13 percent but accounts for more than a third of healthcare expenditures. That number will increase significantly over the next 25 years. It’s estimated that by 2050, one-fifth of the total population in the United States will be aged 65 and older, and healthcare costs will rise at a simila

article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A